Chronic HBV Infection Clinical Trial
Official title:
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics of Single Ascending Dose (SAD) of PA1010 Tablets in Chinese Healthy Subjects and the Effects of Food and Gender on Pharmacokinetics
Verified date | July 2022 |
Source | Zhejiang Palo Alto Pharmaceuticals, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objectives of this study are to evaluate the safety, tolerability and pharmacokinetics characteristics of single ascending dose (SAD) of PA1010 tablets in Chinese healthy adults and the impact of food and gender on the pharmacokinetics
Status | Completed |
Enrollment | 80 |
Est. completion date | December 12, 2020 |
Est. primary completion date | December 12, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: 1. Male or female subjects aged between 18 and 55 (including upper and lower limits); 2. Body mass index (BMI) is between 18 and 28 kg/m2 (including upper and lower limits); 3. During the study period (from signing the informed consent to the last follow-up) and within 90 days after the last dose, there is no possibility of pregnancy (or making the sexual partner pregnant), childbirth or lactation, including: 1. Menopausal women who have menopause for more than 12 months or undergo sterilization (such as hysterectomy or bilateral ovariectomy); 2. Postmenopausal women, who have negative urine pregnancy test within 24 hours before the first dose, are willing to take more than one effective contraceptive method from the screening period to 90 days after the last dose, including intrauterine device, fallopian tube ligation, double barrier method (condom / vaginal diaphragm + spermicide) and male partner vas deferens ligation, but do not include oral contraceptives; 3. Men are willing to take more than one effective contraceptive method from the first dose to 90 days after the last dose, including vasectomy, double barrier method, female partner's use of contraceptives, intrauterine device or tubal ligation, etc.; 4. Avoid sex during the study period to 90 days after the last dose; 4. There is no history of major diseases, and the physical examination, vital signs, electrocardiogram and laboratory examination results during the screening period are normal, or although they exceed the normal reference value range, they are judged by the researcher to be of no clinical significance; 5. Be able to communicate with clinical staff normally and comply with the requirements of this study; 6. Sign the informed consent form to indicate willingness to participate in this study. Exclusion Criteria: 1. Any medical condition that the investigator considers to be likely to increase the risk of study participation (in particular, a history of esophageal or gastrointestinal ulcers), that may interfere with drug absorption, distribution, metabolism, or excretion, or that may impair adherence to the study protocol; 2. Those who have received any other study drug within 90 days before the first dose of the study drug; 3. Those who have received other prescription or over-the-counter drugs that will effect the study evaluation considered by the investigator that within 14 days prior to the first administration of the study drug (or within 5 half-lives of the drug, whichever is longer); 4. Those who have donated blood or lost a lot of blood (>400 ml) within 3 months before the first dose of the study drug; 5. Major surgery or great trauma within 6 months before the first dose of the study drug (the investigator make the judgement based on the previous medical history); 6. Consumption of beverages or foods containing grapefruit, pomegranate, papaya, grapes, carambola within 14 days, or do not agree to refrain from taking those beverages or foods every day during the study; 7. Any alcoholic products within 48 hours before the first administration of the study drug, or disagree to refrain from taking any alcohol products every day during the study; 8. Any foods or beverages rich in caffeine and xanthine within 48 hours before the first dose of the study drug(coffee, tea, coke, chocolate, seafood, animal liver, etc.) or disagree to refrain from taking those foods and beverages every day during the study; 9. Abnormal ECG during screening or baseline period, which is judged to be clinically significant by the investigator; Or QTcF > 450 ms during screening or baseline period; 10. History of heart disease, including a family history of sudden death caused by cardiac causes or QT interval prolongation syndrome; 11. History of serious kidney disease (judged by the investigator); 12. Difficulty in venous blood collection, or known to have a history of needle fainting and blood fainting for many times; 13. Clinical or laboratory evidence shows that there is one of the following situations: hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), syphilis carrying / infection; 14. Any history of food and drug allergy of clinical significance judged by the investigator; 15. Any history of drug abuse or urine drug test (+) in the screening period within 1 year before the first administration of the study drug; 16. Regular drinking history within 6 months before screening. Women have more than 7 cups / week, men have more than 14 cups / week (1 cup =5 ounces of wine or 12 ounces of beer or 1.5 ounces of spirits) or the alcohol test exceeds the standard during the screening period; 17. Those who cannot quit smoking as required during the study period or whose cigarette test paper (urine nicotine test) is positive during the screening period; 18. Participated in this study before. |
Country | Name | City | State |
---|---|---|---|
China | Affiliated Hospital of Xuzhou Medical University | Xuzhou | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
Zhejiang Palo Alto Pharmaceuticals, Inc. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of subjects having abnormal hematology laboratory parameters | Absolute and relative number of subjects with values below, within or above the normal range will be assessed. | Up to 72 hours after last dose | |
Primary | Number of subjects with abnormal clinical chemistry parameters | Absolute and relative number of subjects with values below, within or above the normal range will be assessed. | Up to 72 hours after last dose | |
Primary | Number of subjects with abnormal values for urinalysis | Absolute and relative number of subjects with values below, within or above the normal range will be assessed. | Up to 72 hours after last dose | |
Primary | Number of subjects with abnormal with blood coagulation function | Absolute and relative number of subjects with values below, within or above the normal range will be assessed. | Up to 72 hours after last dose | |
Primary | Ear temperature | Vital sign-ear temperature | Up to 72 hours after last dose | |
Primary | Systolic and diastolic blood pressure | Vital sign-Systolic and diastolic blood pressure | Up to 72 hours after last dose | |
Primary | Pulse rate | Vital sign-Pulse rate | Up to 72 hours after last dose | |
Primary | Breathing rate | Vital sign-Breathing rate | Up to 72 hours after last dose | |
Primary | ECG parameter-QTc interval | A 12 lead electrocardiogram (ECG) will be recorded using an ECG machine that automatically calculates the QTc intervals | Up to 72 hours after last dose | |
Primary | ECG parameter-PR interval | A 12 lead electrocardiogram (ECG) will be recorded using an ECG machine that automatically measures PR intervals | Up to 72 hours after last dose | |
Primary | ECG parameter-QRS duration | A 12 lead electrocardiogram (ECG) will be recorded using an ECG machine that automatically measures QRS duration | Up to 72 hours after last dose | |
Primary | Number of subjects experiencing adverse events (AEs) | An adverse event (AE) is defined as any untoward medical occurrence in a clinical study subject administered a medicinal product which does not necessarily have a causal relationship with this treatment. | Up to 4days after the last dose | |
Primary | Pharmacokinetics of single dose of PA1010-Cmax | Blood samples will be collected serially, and the concentrations of PA1010 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Maximum Observed Plasma Concentration (Cmax) | Up to 72 hours after last dose | |
Primary | Pharmacokinetics of single dose of PA1010-Tmax | Blood samples will be collected serially, and the concentrations of PA1010 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Time to Reach Maximum Observed Plasma Concentration (Tmax) | Up to 72 hours after last dose | |
Primary | Pharmacokinetics of single dose of PA1010-AUC | Blood samples will be collected serially, and the concentrations of PA1010 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Area Under the Plasma Concentration-Time Curve (AUC) | Up to 72 hours after last dose | |
Secondary | Pharmacokinetics of single dose of PA1010-T1/2 | Blood samples will be collected serially, and the concentrations of PA1010 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Elimination Half-Life Period (T1/2) | Up to 72 hours after last dose | |
Secondary | Pharmacokinetics of single dose of PA1010-Vz/F | Blood samples will be collected serially, and the concentrations of PA1010 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Apparent Volume of Distribution(Vz/F) | Up to 72 hours after last dose | |
Secondary | Pharmacokinetics of single dose of PA1010-?z | Blood samples will be collected serially, and the concentrations of PA1010 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Elimination Rate Constant(?z) | Up to 72 hours after last dose | |
Secondary | Pharmacokinetics of single dose of PA1010-CL/F | Blood samples will be collected serially, and the concentrations of PA1010 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Apparent Clearance(CL/F) | Up to 72 hours after last dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04470388 -
A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment
|
Phase 1 | |
Completed |
NCT05019040 -
Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV Patients
|
Phase 1/Phase 2 | |
Completed |
NCT01943799 -
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
|
Phase 2 | |
Recruiting |
NCT05792761 -
A Study on Antiviral Treatment of Chronic Hepatitis B in Children
|
N/A | |
Completed |
NCT04008004 -
A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)
|
Phase 1 | |
Active, not recruiting |
NCT05734807 -
A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia
|
Phase 2 | |
Completed |
NCT06029634 -
Effects of T-bet B Cells in Persistent Virus Control After Discontinuance of NAs in CHB Patients
|
||
Completed |
NCT04147208 -
Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection
|
Phase 2 | |
Completed |
NCT03909191 -
Serum HBV RNA Value on Chronic Hepatitis B Virus Infection Manage
|
||
Completed |
NCT03664518 -
to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection
|
Phase 2 | |
Completed |
NCT05542979 -
A Study to Evaluate the Safety, Tolerability of HH-003 Injection in Participants With Chronic Hepatitis B Virus Infection
|
Phase 1 | |
Active, not recruiting |
NCT03903796 -
Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection
|
Phase 3 | |
Completed |
NCT05851261 -
Study to Evaluate the Safety, Tolerance, Pharmacokinetics Characteristics of PA3670 Tablets in Chinese Healthy Subjects
|
Phase 1 |